<DOC>
	<DOC>NCT02002962</DOC>
	<brief_summary>The aim of this randomized study was to assess the effectiveness of endomyocardial botulinum toxin injection for preventing post-procedural atrial fibrillation in patients undergoing the radiofrequency ablation of atrial flutter.</brief_summary>
	<brief_title>Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter</brief_title>
	<detailed_description />
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Age â‰¥ 18 years ECG documented paroxysmal or persistent AFL No prior documented history of AF Patient undergoing RFA of AFL. No indication (other than AFL) for continued anticoagulation with warfarin. No existing implantable cardiac device (pacemaker, defibrillator, cardiac resynchronization therapy device) A history of atrial fibrillation Previous AF ablation procedure Congestive heart failure Left Ventricle ejection fraction less than 35% Unwillingness to participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>